LinkedIn Profile

Access CartiHeal historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:cartiheal 1031481 Nov 18th, 2019 12:00AM CartiHeal 669 21.00 Open Medical Device Nov 18th, 2019 03:58PM Nov 18th, 2019 03:58PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 17th, 2019 12:00AM CartiHeal 669 21.00 Open Medical Device Nov 17th, 2019 04:23PM Nov 17th, 2019 04:23PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 16th, 2019 12:00AM CartiHeal 669 21.00 Open Medical Device Nov 16th, 2019 04:18PM Nov 16th, 2019 04:18PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 15th, 2019 12:00AM CartiHeal 668 21.00 Open Medical Device Nov 15th, 2019 12:54PM Nov 15th, 2019 12:54PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 13th, 2019 12:00AM CartiHeal 667 21.00 Open Medical Device Nov 13th, 2019 01:18PM Nov 13th, 2019 01:18PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 12th, 2019 12:00AM CartiHeal 666 21.00 Open Medical Device Nov 12th, 2019 03:01PM Nov 12th, 2019 03:01PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 11th, 2019 12:00AM CartiHeal 665 21.00 Open Medical Device Nov 11th, 2019 02:59PM Nov 11th, 2019 02:59PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 10th, 2019 12:00AM CartiHeal 665 21.00 Open Medical Device Nov 10th, 2019 06:05PM Nov 10th, 2019 06:05PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 9th, 2019 12:00AM CartiHeal 666 21.00 Open Medical Device Nov 9th, 2019 05:32PM Nov 9th, 2019 05:32PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology
private:cartiheal 1031481 Nov 8th, 2019 12:00AM CartiHeal 666 21.00 Open Medical Device Nov 8th, 2019 02:43PM Nov 8th, 2019 02:43PM CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study. Open Open 17 Atir Yeda Kfar Saba Israel IL 4464313 Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.